Recent advances in SARS-CoV-2 Spike protein and RBD mutations comparison between new variants Alpha (B.1.1.7, United Kingdom), Beta (B.1.351, South Africa), Gamma (P.1, Brazil) and Delta (B.1.617.2, India)

Autor(es)

Sanches, Paulo R. S. ^[1] ; Charlie-Silva, Ives ^[2] ; Braz, Helyson L. B. ^[3] ; Bittar, Cintia ^[4] ; Calmon, Marilia Freitas ^[4] ; Rahal, Paula ^[4] ; Cilli, Eduardo M. ^[1]

Afiliação do(s) autor(es)

^[1] Sao Paulo State Univ, Inst Chem, UNESP, Araraquara, SP - Brazil

^[2] Univ Sao Paulo, Inst Biomed Sci, Dept Pharmacol, Sao Paulo, SP - Brazil

^[3] Univ Fed Ceara, Dept Morphol, Sch Med, Fortaleza, Ceara - Brazil

^[4] Sao Paulo State Univ, Inst Biosci Language & Exact Sci, UNESP, Sao Jose Do Rio Preto, SP - Brazil

• Tipo de documento: Artigo Científico
• Fonte: JOURNAL OF VIRUS ERADICATION; v. 7, n. 3 SEP 2021.
• Citações Web of Science: 0

Resumo

New variants of SARS-CoV-2 Alpha (B.1.1.7); Beta (B.1.351) Gamma (P.1) and Delta (B.1.617.2) quickly spread in the UK, South Africa, Brazil and India, respectively. To address whether mutations in SARS-CoV-2 RBD spike protein could affect virus infectivity, peptides containing RBD amino acids mutations have been constructed and interacted with human ACE2 by computational methods. Our results suggest that mutations in RBD amino acids K417, E484, L452, T478 and N501 are expressively increasing the affinity of this protein with human angiotensin-converting enzyme 2 (ACE2), consequently, variants Alpha (B.1.1.7), Beta (B1.351), Gamma (P.1) and Delta (B.1.617.2) could be more infective in human cells compared with SARS-CoV-2 isolated in Wuhan2019 and the Gamma and Delta variants could be the most infective among them. (AU)

• Processo FAPESP: 20/12519-4 - Estudo da ação de peptídeos sintéticos como antivirais contra o SARS-CoV-2 (COVID-19) e avaliação combinada com anti-inflamatórios comerciais
• Beneficiário: Paulo Ricardo da Silva Sanches
• Modalidade de apoio: Bolsas no Brasil - Pós-Doutorado
• Processo FAPESP: 20/05761-3 - Estudo da ação de peptídeos sintéticos como antivirais contra o SARS-CoV-2 (COVID-19) e avaliação combinada com anti-inflamatórios comerciais
• Beneficiário: Eduardo Maffud Cilli
• Modalidade de apoio: Auxílio à Pesquisa - Regular